Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI analyzes CT scans to find safer radiation levels for liver cancer patients

NCT ID NCT07346573

Knowledge-focused Sponsor: Cao peiguo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study used artificial intelligence to examine CT scans from 274 liver cancer patients who had already received radiation therapy. The goal was to find the radiation dose that causes a visible liver reaction, which could help doctors avoid liver injury in future treatments. Researchers compared patients who developed this reaction with those who did not, looking at scan features and clinical information. Since this was a retrospective study, no new treatments or procedures were given to participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors set safer radiation doses for liver cancer treatment, reducing the risk of liver injury.
What could go wrong
This is a retrospective observational study, so it can show patterns but cannot prove cause and effect. The findings may not apply to all patients or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

274 people

The number who actually took part.

Started

May 2019

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (≥18 years) with primary or metastatic liver malignancies who received liver radiotherapy (e.g., SBRT or IMRT) at the Third Xiangya Hospital of Central South University between July 2015 and September 2024 , and had complete dosimetric data and follow-up CT imaging available for retrospective analysis.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Primary or secondary liver malignancies, including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and secondary liver tumors. * Liver function of Child-Pugh classification A or B. * Completed EBRT treatment as planned. * No other local treatment of liver lesions between EBRT and the follow-up imaging examination. * Complete imaging re-examination data. * Three-phase enhancement CT scans showing typical Focal Liver Reaction (FLR). * The registration effect of follow-up CT and planning CT is satisfactory. Exclusion Criteria: * History of upper abdominal radiotherapy or liver transplantation. * Failure to complete radiotherapy as scheduled. * Previous cancer treatment-related toxicities that did not return to baseline or grade 0-1 (except for hair loss and peripheral neuropathy).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma intrahepatic cholangiocarcinoma liver and intrahepatic bile duct neoplasm Liver Neoplasms radiation injury secondary neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver neoplasms Radiation-induced liver injury

Contacts and locations

Locations

  • The Third Xiangya Hospital

    Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.